It is made available under a [CC-BY 4.0 International license](http://creativecommons.org/licenses/by/4.0/) .

The effect of protein levels of ABO on pregnancy related out- ¹ **comes**: **a Mendelian randomization study** ²

Yuqi Sun†1,2,3, Haonan Zheng†1,3,4, Manqing Wang†1,2,3, Rongrong Gu†1,2,3, Xueyan Wu1,3, Qian Yang5, Huiling Zhao*5, 3 **Yufang Bi*1,3, Jie Zheng*1,3,5** 4

- ¹ Department of Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, 5 Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China 6
- ² College of Health Science and Technology, Shanghai Jiao Tong University School of Medicine 7
- 3 Shanghai National Clinical Research Center for metabolic Diseases, Key Laboratory for Endocrine and Met- 8 abolic Diseases of the National Health Commission of the PR China, Shanghai Key Laboratory for Endo- 9 crine Tumor, Shanghai Digital Medicine Innovation Center, Ruijin Hospital, Shanghai Jiao Tong University 10 School of Medicine, Shanghai, China 11
- ⁴ College of Basic Medical Science, Shanghai Jiao Tong University School of Medicine 12
- ⁵ MRC Integrative Epidemiology Unit (IEU), Bristol Medical School, University of Bristol, Oakfield House, 13 Oakfield Grove, Bristol, BS8 2BN, United Kingdom 14
- † Equal contribution 15
- ***** Correspondence: 16
- ¹ Yufang Bi, Department of Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic 17 Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China, E-mail: 18 byf10784@rjh.com.cn 19
- ² Huiling Zhao, MRC Integrative Epidemiology Unit (IEU), Bristol Medical School, University of Bristol. 20 Population Health Sciences, Bristol Medical School, University of Bristol. United Kingdom. Tel: +44 117 455 21 3987; Email: tq20202@bristol.ac.uk 22
- 3 Jie Zheng, Department of Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic 23 Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China, E-mail: 24 zj12477@rjh.com.cn 25

Abstract: Protein level of Histo-Blood Group ABO System Transferase (ABO) has been reported to 26 be associated with cardiometabolic diseases. But its effect on pregnancy related outcomes was still 27 unclear. Here we conducted a two-sample Mendelian randomization study to ascertain the putative 28 causal roles of protein levels of ABO in pregnancy related outcomes. Cis-acting protein quantitative 29 trait loci (pQTLs) robustly associated with protein level of ABO ($P < 5x10-8$) were used as instru- 30 ments to proxy the ABO level (N = 35,559, data from deCODE), with two additional pQTL datasets 31 from Fenland ($N = 10,708$) and INTERVAL ($N = 3,301$) used as validation exposures. Ten pregnancy 32 related diseases and complications were selected as outcomes. We observed that a higher protein 33 level of ABO showed a putative causal effect on venous complications and haemorrhoids in preg- 34 nancy (OR = 1.207, 95%CI = 1.107-1.316, colocalization probability = 91.3%), which was validated by 35 using pQTLs from Fenland and INTERVAL. The Mendelian randomization results further showed 36 effects of the ABO protein on gestational hypertension (OR = 0.974, 95%CI = 0.953-0.995), despite 37 insignificance after multiple testing correction and little colocalization evidence. Sensitivity analyses, 38 including proteome-wide Mendelian randomization of the cis-acting ABO pQTLs, showed little ev- 39 idence of horizontal pleiotropy. Correctively, our study prioritised ABO as a putative causal protein 40 for venous complications and haemorrhoids in pregnancy. Future epidemiology and clinical studies 41 are needed to investigate whether ABO can be considered as a drug target to prevent adverse preg- 42 nancy outcomes. 43

Keywords: Mendelian randomization; ABO; venous complication in pregnancy; gestational hyper- 44 tension and the state of th

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

It is made available under a [CC-BY 4.0 International license](http://creativecommons.org/licenses/by/4.0/) .

Adverse pregnancy outcomes, e.g. pregnancy induced venous complications (PIVC), 48 gestational hypertension, gestational oedema and preterm labor, are health conditions re- 49 lated to both pregnant women and newborns, and always arose concerns in our society. 50 Recent studies indicated that preterm labor is a leading cause of perinatal morbidity and 51 mortality in developed countries[1]. PIVC includes pregnancy related deep vein throm- 52 bosis and lower limb varicose veins, causes lower limb swelling, pain, skin ulcers, and 53 difficulties for the daily activities (e.g. sleep), and even threatens lives of pregnant 54 women[2]. Hemorrhoids can be considered as a common venous disease that has a signif- 55 icant impact on quality of life for pregnant women[3]. Gestational hypertension is a major 56 cause of maternal, fetal and newborn morbidity and mortality, and women with preg- 57 nancy-induced hypertension syndrome are at higher risks of abruptio placentae, cerebro- 58 vascular events, organ failure and disseminated intravascular coagulation[4]. Identifica- 59 tion of genetic regulators that influence pregnancy related outcomes will help better un- 60 derstand the etiology of these conditions, and may support the development of drug tar- 61 gets to reduce risks of these outcomes. 62

ABO blood group system classifies human blood into four main types: A, B, AB, and 63 O, which indicates the presence or absence of specific antigens on the surface of red blood 64 cells. It is genetically determined by the ABO gene (chromosome 9, q34.2), and the gene 65 mutations in the region influence the blood group. ABO blood group is proved to be re- 66 lated to a wide range of diseases, especially cardiovascular ones^[5]. Julia Hoglund et al. 67 characterized the human ABO genotypes and their associations with common inflamma- 68 tory and cardiovascular diseases. They found that ABO gene mutations was significantly 69 associated with individual thrombotic risk[6]. Several studies observed the associations 70 of ABO blood group system with pregnancy related outcomes, including stillbirth[7] and 71 obstetrical hemorrhage risk[8]. Additionally, pregnant women with type O blood had a 72 lower risk of cardiovascular disease comparing to those with type A, type B and type 73 AB[9]. Yet the evidence supporting the association between ABO blood group and preg- 74 nancy related outcomes is still limited, requiring large birth cohorts or record-linkage data. 75 This inspired us to further investigate the function of plasma protein level of ABO (i.e., 76 Histo-Blood Group ABO System Transferase) on top of the traditional blood tests, in order 77 to understand the relationships between the ABO level and pregnancy related outcomes. 78

Given it would not be feasible to conduct a randomized control trail among pregnant 79 women due to ethical concerns[10], Mendelian randomization (MR) provides an alterna- 80 tive way to assess the impact of ABO protein level on pregnancy outcomes. Two-sample 81 MR is a genetic epidemiology method using germline genetic variants (also called single 82 nucleotide polymorphisms (SNPs)) as instruments to estimate the causal effect of an ex- 83 posure on an outcome[11]. Previous MR studies identified effects of protein level of ABO 84 on many diseases, including COVID-19[12] and ischemic stroke[13]. However, its casual 85 relationships with pregnancy related outcomes remain unclear. Recently available large- 86 scale genome-wide association studies (GWASs) of protein level of ABO[14-16], and ad- 87 verse pregnancy outcomes[17-19] provided a timely opportunity to investigate the causal 88 effect of the ABO level on those outcomes using MR. 89

The aim of this study was to estimate the casual associations of protein level of ABO 90 with ten pregnancy related outcomes using two-sample MR. To increase reliability of the 91 findings, the causal estimates were validated in three independent ABO datasets (de- 92 CODE[14] ,Fenland[15] and INTERVAL[16]). To further increase the possibility of identi- 93 fying true causality, we applied a sensitivity analysis pipeline[20], including Steiger filter- 94 ing[21], and genetic colocalization[22-24]. Given pleiotropic potential of the ABO instru- 95 ments, we applied a proteome-wide MR to further investigate the possibility of horizontal 96 pleiotropy. 97

Results 98

In this study, MR analyses and Steiger filtering tests were performed using the 99 TwoSampleMR package, and colocalization analysis were conducted using the coloc 100

It is made available under a [CC-BY 4.0 International license](http://creativecommons.org/licenses/by/4.0/) .

package. Results were visualized using the ggplot2 and LocusZoom[25] in the R software 101 platform (version 4.2.2; R Development Core Team). 102

Summary of ABO instrument selection 104

We selected two instruments (rs1053878 and rs950529388) associated with protein 105 level of ABO that reached the genome-wide significance (P-value < 5x10−8) in the discov- 106 ery cohort (i.e.*,* deCODE). The instrument strength of a combination of these two instru- 107 ments were strong (total F statistic = 18667.266), where each of the individual instrument 108 also showed a strong strength (Table S1A). The two ABO instruments were weakly corre- 109 lated with each other (LD $r2 < 0.3$), and were used in the discovery MR analyses (Table 110 S4A). Other two sets of instruments (two instruments selected from Fenland and one in- 111 struments selected from INTERVAL) were used to proxy ABO protein level in the valida- 112 tion MR analyses (Table S2 and S3). All the five selected instruments were common vari- 113 ants with a minor allele frequency > 0.05, passed the Steiger filtering test of directionality 114 (Table S7A, S7B and S7C) and were not palindromic SNPs with minor allele frequencies 115 larger than 0.42. 116

Effect of protein levels of ABO on pregnancy related outcomes using deCODE data 117

Figure 2 visualizes the pregnancy outcomes achieving statistical significance before 118 FDR correction. Table 1 and Figure 3 present two-sample MR estimates for associations of 119 ABO pQTL in deCODE with pregnancy-related outcomes. In the discovery analysis, MR 120 suggested that higher protein levels of ABO showed a putative causal effect on increased 121 risks of pregnancy induced venous complications and haemorrhoids in pregnancy (OR = 122 1.207; 95% confidence interval [95% CI]: 1.107–1.316; FDR-adjusted P-value = 2.008 x 10-4) 123 (Figure 3). Strong evidence of colocalization indicated that venous complications and 124 haemorrhoids in pregnancy (colocalization probability = 91.3%) shared the same causal 125 variants with the protein level of ABO (Table 1). The MR analyses for other pregnancy 126 related outcomes did not reach the FDR threshold, and their colocalization analyses fur- 127 ther suggested little evidence of causal effects on those outcomes. Through the LD check 128 between ABO pQTLs and venous complications, we identified that one SNP (rs687621, 129 merged with our instrument - rs950529388) in deCODE was strongly correlated with the 130 leading SNP in the outcome dataset (LD $r2 > 0.8$), suggesting a potential causal relation-131 ship. However, LD check for the other instrument (rs1053878) did not show such a rela- 132 tionship (Figure 4). 133

Effect of protein levels of ABO on pregnancy related outcomes using Fenland and INTERVAL 134 *data* 135

In Table 1 and Figure 3, ABO pQTL was consistently associated with venous compli- 136 cations and haemorrhoids in pregnancy using data from Fenland and INTERVAL (OR = 137 1.263; 95% CI: 1.143–1.396; FDR-adjusted P-value = 5.001 x 10-5, OR = 1.248; 95% CI: 1.135– 138 1.372; FDR-adjusted P-value = 4.782 x 10-5, respectively). These estimates were also con- 139 sistent with findings from the discovery analysis, suggesting the robustness of the causal 140 relationship between ABO and venous complications. Consistent with the discovery MR, 141 associations of ABO pQTL with other pregnancy related outcomes did not reach our FDR 142 threshold here (Table 1 and Figure 3). 143

Positive control analysis of protein levels of ABO on T2D 144

A higher protein level of ABO was associated with an increased risk of T2D using 145 data from deCODE (OR = 1.038, 95%CI: 1.028–1.048, P = 9.421×10-15), Fenland (OR = 1.047, 146 95% CI: 1.036–1.059, P-value = 1.506×10-16) and INTERVAL (OR = 1.044, 95%CI: 1.034– 147 1.055, P-value = 2.091×10^{-16}). Colocalization analysis also supports the causal effect of 148 ABO pQTL on T2D (colocalization probability = 95.3%; Table1). 149

It is made available under a [CC-BY 4.0 International license](http://creativecommons.org/licenses/by/4.0/) .

Proteome-wide association study of ABO instruments and MR of potential pleiotropy proteins on 150 *pregnancy related outcomes* 151

To estimate the influence of horizontal pleiotropy on the MR findings, we first looked 152 up the genetic associations of ABO instruments on all available proteome GWAS listed in 153 the IEU OpenGWAS database (prot-a,prot-b and prot-c; Table S8 and S9). We found that 154 the two ABO instruments from deCODE (i.e., rs1053878 and rs950529388 (merged into 155 rs687621)) were associated with 108 proteins in total, besides ABO protein. For these 108 156 proteins, we extracted their instruments and conducted two-sample MR of these proteins 157 on our pregnancy related outcomes. We found that none of these proteins was associated 158 with venous complications and haemorrhoids in pregnancy with Bonferroni-adjusted P- 159 values ≤ 0.01 , which implies that unbalanced horizontal pleiotropy is less likely to be an 160 issue for our MR results. We also identified that two proteins (toll-like receptor 4: lym- 161 phocyte antigen 96 complex and lactase-phlorizin hydrolase) were associated with GDM 162 and GH, respectively (Bonferroni-adjusted P-values <0.01, Table S10). Using multivari- 163 able MR to adjust for these two proteins, we found little evidence for the association of 164 ABO protein with GDM or GH (Table S11 and S12), which were consistent with our uni- 165 variable MR results in Table 1. 166

It is made available under a [CC-BY 4.0 International license](http://creativecommons.org/licenses/by/4.0/) .

Discussion 168

In this study, we estimated the causal relationships of protein levels of ABO on ten 169 pregnancy related outcomes using two-sample MR, and validated the findings in three 170 independent datasets of ABO pQTL (deCODE as discovery, Fenland and INTERVAL as 171 validation). Our study, for the first time, showed that one standard deviation higher of 172 protein level of ABO was associated with an increased risk of pregnancy induced venous 173 complications and haemorrhoids in pregnancy, while the other 55 proteins showed little 174 evidence for an effect with this outcome. Sensitivity analyses including genetic colocali- 175 zation and proteome-wide MR of potential pleiotropic instruments further strength the 176 possibility of identifying true causal effects in this finding. 177

Comparison with previous studies 179

In order to compare our top findings with previous literature, we comprehensively 180 reviewed both conventional observational studies and MR studies estimating associations 181 of ABO with any health outcomes. However, we did not identify any specific articles ex- 182 ploring an effect of circulating ABO protein on pregnancy related diseases or symptoms. 183 Most existing studies focused on ABO blood group types, and found some associations 184 with not only pregnancy outcomes (discussed below), but also outcomes in general pop-
185 ulation (e.g. cardiovascular diseases[26], knee osteoarthritis[27], stroke[28], throm- 186 bosis[29-31] and T2D[5]). 187

Our novel finding for the positive association of ABO protein expression in plasma 188 with venous complications and haemorrhoids in pregnancy might not be directly com- 189 pared to the previous studies investigating ABO blood group among the general popula- 190 tion. Previous studies consistently showed that non-O blood group individuals had a sig- 191 nificantly increased risk of venous thrombosis compared to O blood group individuals 192 (i.e., non-ABO protein secretion), and the risk of thrombosis is likely to be inversely cor- 193 related with the expression of ABH antigens[29-31]. Additionally, consistent with our 194 findings among pregnant women, ABO pQTL was found to be associated with venous 195 thromboembolism in non-pregnant population[16]. Such evidence suggests that the ABO 196 protein could be a significant new drug target to prevent venous complication during 197 pregnancy by regulating the expression of ABH antigen. 198

Hypertensive disorders of pregnancy constitute one of the leading causes of maternal 199 and perinatal mortality worldwide[32], and have been reported closely relating to ABO 200 blood groups[33]. Our study provided some evidence to further support the casual rela- 201 tionship between ABO protein and gestational hypertension in the discovery analysis, alt- 202 hough the findings did not pass FDR tests in the three datasets. It is worth mentioning 203 that ABO plasma protein level and gestational hypertension across the three datasets 204 showed similar effect estimates, suggesting that a higher level of ABO plasma protein 205 might probably reduce the risk of gestational hypertension. Combing our finding for the 206 unfavorable associations with venous complications, further studies need to confirm the 207 protective effect on gestational hypertension, so as to inform antenatal care services to 208 keep the ABO plasma protein within a proper range. 209

Previous observational studies showed conflicted results for the association of ABO 210 level pre-eclampsia[34, 35], and our study provided little evidence for an association of 211 ABO plasma protein level with pre-eclampsia. GDM is supposed to be closely related to 212 T2D, and genome-wide association studies showed multiple lines of evidence pointed to 213 the shared pathophysiology of GDM and T2D[36]. Recent studies also suggested that O 214 blood group was independently associated with a higher risk of GDM[37], and AB blood 215 group was considered as a protective factor[38]. Although we confirmed the causal rela- 216 tionship between ABO plasma protein level and T2D, there was little evidence supporting 217 a causal relationship between ABO plasma protein level and GDM in our study. This 218 could be due to insufficient power of the GDM GWAS, potential horizontal pleiotropy via 219

It is made available under a [CC-BY 4.0 International license](http://creativecommons.org/licenses/by/4.0/) .

other proteins, or suggests that the occurrence of T2D and GDM may be regulated by 220 slightly different mechanisms. 221

222

Strength and limitation 223

Key strengths of this study include that 1) to the best of our knowledge, it is the first 224 study to use MR to explore associations of ABO protein with pregnancy outcomes; 2) com- 225 prehensive sensitivity analyses (e.g., positive control outcome, Steiger filtering, colocali- 226 zation and proteome-wide MR) were applied to minimize potential bias due to violations 227 of MR assumptions; 3) we investigated a range of adverse pregnancy outcomes in one 228 paper. 229 and 229 and

However, limitations do exist. First, this study may be vulnerable to insufficient sta- 230 tistical power, as the numbers of cases ranged between 478 to 30971 for our outcomes. 231 Although we identified statistically significant association with venous complications (the 232 outcome with the smallest N cases), true causal effects on other outcomes (e.g., GDM) may 233 be too small to be detect under the current sample sizes. Second, FinnGen defined venous 234 symptoms and haemorrhoids in pregnancy (O22 in ICD-10) by combining multiple sub- 235 types (O22.0 to O22.9 in ICD-10). Given we used summary-level data, we could not ex- 236 plore associations of ABO protein expression with those subtypes separately. Addition- 237 ally, we noticed that both FinnGen and UK Biobank (field ID: 47270 and 47271) had very 238 limited numbers of haemorrhoids cases based on their record linkage data of secondary 239 care, even if this is expected to be a common disease in pregnancy[2]. This inconsistency 240 could be because most patients did not have haemorrhoids severe enough to access to in- 241 patient services. Thus, our results should be interpreted as the causal effect on severe ve- 242 nous conditions. Further studies based on self-report or primary care data are needed to 243 investigated common diseases in pregnancy. Third, FinnGen included women with pre- 244 existing disorders (e.g., diabetes and hypertension) into the case groups, and did not ex- 245 clude never pregnant women from the controls. Fourth, our genetic instruments were ob- 246 tained from non-pregnant population, and we have to assume that the SNP-exposure as- 247 sociations are not varied during pregnancy. Fifth, our MR results may still be prone to 248 horizontal pleiotropy due to paternal or fetal genotype^[39]. We did not adjust for them 249 because of limited publicly available GWAS data. Finally, our results are limited to 250 women of European descent, and we cannot assume that they generalize to other popu- 251 lations. 252

Conclusions 253

Our results suggest that plasma ABO protein level was causally associated with a 254 higher risk of venous complications and hemorrhoids in pregnancy, which was unlikely 255 to be influenced by horizontal pleiotropy. Our findings support prioritising ABO as a po- 256 tential drug target for T2D and the pregnancy complications. However, we acknowledge 257 the needs for further MR studies based on larger GWAS of pregnancy outcomes, large 258 observational studies, and studies in women of non-European ancestries. 259

It is made available under a [CC-BY 4.0 International license](http://creativecommons.org/licenses/by/4.0/) .

Materials and Methods 261

Genetic instruments selection of ABO protein levels 262

Figure 4 presented the study design. Cis-acting protein quantitative trait loci (pQTLs) 263 from three proteome GWAS studies were used as candidate instruments for the discovery 264 (deCODE $n = 35,559$) and validation (Fenland $n = 10,708$ and INTERVAL $n = 3,301$) MR 265 analyses. The following criteria were applied for the instrument selection: 266

- a) we only selected cis-acting pQTLs (defined as genetic variants ≤ 500 kb from the lead- 267 ing pQTL within the ABO region) since cis-acting pQTLs are more likely to have direct 268 biological functions; 269
- b) we selected pQTLs that were robustly associated with protein level of ABO (P-value 270 $\text{threshold} \leq 5 \times 10.8$; 271
- c) we conducted linkage disequilibrium (LD) clumping for the instruments to identify 272 pQTLs to proxy protein level of ABO in MR using generalized inverse variance weighted 273 (gIVW) (threshold of LD r2 \leq 0.3 for exclusion of highly correlated pQTLs). 274

After selection, three groups of cis-acting pQTLs (two from deCODE [Table S1]; two 275 from Fenland [Table S2]; one from INTERVAL [Table S3]) were used as instruments for 276 the subsequent MR analyses (LD matrix among instruments were listed in [Table S4A, 4B 277 and 4C]); Instruments from deCODE were selected for discovery analyses since it has the 278 largest sample size among the three datasets, and the other two were used for validation 279 analyses. The strength of genetic instruments was evaluated using F-statistic, with an F- 280 statistic > 10 suggesting a strong instrument[40]. 281

Genetic associations of pregnancy outcomes 282

A total of ten pregnancy related diseases and complications were selected as out- 283 comes for this study, including venous complications and hemorrhoids in pregnancy, ges- 284 tational hypertension, pre-eclampsia, infections of genitourinary tract in pregnancy, ges- 285 tational oedema and proteinuria without hypertension, preterm labor and delivery, spon- 286 taneous abortion, gestational diabetes mellitus (GDM), and other outcomes related to 287 childbirth(Table S5). Type 2 diabetes (T2D) was selected as a positive control outcome 288 since its association with protein level of ABO has already been confirmed (Table S6)[41]. 289 To avoid sample overlap with pQTL GWAS, we obtained GWAS summary statistics (in- 290 cluding estimates of regression coefficient, the corresponding standard error and P value, 291 effect allele, other allele, and effect allele frequency) for all the outcomes from FinnGen[19]. 292 *Steiger filtering* 293

With large sample sizes of the exposure and outcome GWAS data, we are likely to 294 identify genetic variants robustly associated with both the exposure and outcomes. There- 295 fore, we may observe reverse causality of genetic variants that influence the outcome first 296 and then influence the exposure as a consequence. To minimise the possibility of reverse 297 causality, we performed Steiger filtering[21] to select valid genetic instruments that 298 showed a right direction of exposure-outcome effect. Steiger filtering assumes that a valid 299 instrument should explain more variance of the exposure than that of the outcome, and 300 identifies those instruments that explained more variance of the outcome than that of the 301 exposure for removal from MR analyses. 302

MR analysis 303

We applied two-sample MR to estimate the effect of protein level of ABO on preg- 304 nancy outcomes (βXY). Wald ratio estimate[42], i.e., the ratio of the genetic association of 305 the outcome ($β$ GY) against the genetic association of the exposure ($β$ GX), was used to 306 estimate the effect based on each instrument. The gIVW with multiplicative random ef- 307 fects[43], was applied to combine the Wald ratio estimates for multiple variants for the 308 same exposure. We conducted the discovery MR by using genetic instruments from de- 309 CODE, and re-conducted gIVW by using those from INTERVAL and Fenland for valida- 310 tion. Since these instruments are obtained from three independent European-based co- 311 horts, the reliability of our MR findings will increase if consistent results are shown across 312

It is made available under a [CC-BY 4.0 International license](http://creativecommons.org/licenses/by/4.0/) .

those datasets. To control for multiple testing, we used Benjamini-Hochberg method to 313 calculate the false discovery rate (FDR) (threshold FDR-adjusted P-value \leq 0.05) for robust 314 **results.** 315

Colocalization analyses 316

We conducted genetic colocalization analyses to detect whether the identified MR 317 signals shared causal variants between the protein expression of ABO and pregnancy out- 318 comes, or were just due to confounding by LD. Under the assumption of a single causal 319 variant within each genomic region, the Bayesian statistical framework quantifies the pos- 320 terior probability of association (PPA) for each of the four possible hypotheses[23] in val- 321 idation analysis (H1/H2: the genetic variants [i.e., pQTLs] were only associated with the 322 protein level of ABO or associated with a pregnancy outcome in the tested genomic region; 323 H3: there were genetic variants associated with both protein expression of ABO and a 324 pregnancy outcome in the tested genomic region but the two traits did not shared the 325 same casual variant; H4: there were genetic variants associated with both protein expres- 326 sion of ABO and a pregnancy outcome, and the two traits shared the same casual variant 327 in the tested genomic region). The effect estimates and allele information for all variants 328 within 500KB window upstream or downstream of the leading pQTL for each trait were 329 extracted for the colocalization analysis. We assigned prior probabilities that a variant is 330 associated with trait 1 (p1 = 1 x 10-4), trait 2 (p2 = 1 x 10-4), and both traits (p12 = 1 x 10-5) 331 as recommended. The PP H4/(PP H3+ PP H4) \geq 70% was considered as the threshold 332 for colocalization tests. We also conducted an LD check analysis between ABO pQTL and 333 the outcome that had showed evidence for colocalizaton using the above Bayesian method, 334 to further validate the results. The LD check window was set up as \pm 500kb, and LD r2 \geq 335 0.8 was considered as evidence for colocalization[20]. 336

Proteome-wide association analysis of ABO instruments and MR of potential pleiotropic proteins 338 *on pregnancy outcomes* 339

It is known that the ABO pQTLs were pleiotropic, being associated with a set of pro- 340 teins[16]. To evaluate the influence of their horizontal pleiotropy, we performed a two- 341 step proteome-wide MR approach using the instruments from deCODE. First, we 342 searched for the genetic effects of each ABO instrument across all publicly available pro- 343 teome-wide GWAS on IEU OpenGWAS[17, 18] to identify its effect on other proteins. 344 These were potential pleiotropic proteins that may link ABO instruments with outcomes 345 not via ABO protein expression. Then we selected those proteins that were associated with 346 our instruments as exposures, and used MR method to check whether there were casual 347 relationships between those potential pleiotropic proteins and our pregnancy outcomes. 348 All pQTLs associated with these potential pleiotropic proteins were used as instruments 349 for this analysis. To control for multiple testing, we used the conservative Bonferroni-ad- 350 justed P-value (i.e., $P \le 0.05$) to define robust MR estimates. Where a pleiotropic protein 351 identified for an outcome, we further conducted a multivariable MR to obtain the direct 352 effect of ABO protein on the outcome adjusting for the pleiotropic protein[44]. 353

354

It is made available under a [CC-BY 4.0 International license](http://creativecommons.org/licenses/by/4.0/) .

Author Contributions: J. Zheng, Y. Bi and H. Zhao contributed to the study conception and design. 355 Material preparation and data collection were performed by R. Gu, M. Wang and J. Zheng; Analyses 356 were performed by H. Zheng, Y. Sun and M. Wang; the manuscript was written by Y. Sun, H. Zheng, 357 R. Gu, M. Wang, X. Wu and Q. Yang, with critical comments from Y. Bi, J. Zheng, H. Zhao, and Q. 358 Yang. All authors commented on previous versions of the manuscript. All authors have read and 359 agreed to the published version of the manuscript. 360

Funding: This project is supported by grants from the National Key Research and Development 361 Program of China (2022YFC2505203). Y. B. is supported by the National Natural Science Foundation 362 of China (82088102, 81970728 and 81941017) and the Shanghai Municipal Education Commission– 363 Gaofeng Clinical Medicine Grant Support (20161307 and 20152508 Round 2). Y. B. is a member of 364 the Innovative Research Team of High-level Local Universities in Shanghai. 365

Data Availability Statement: This study only used publicly available GWAS summary statistics 366 from deCODE, Fenland, INTERVAL, FinnGen [\(https://www.finngen.fi/en\)](https://www.finngen.fi/en) and IEU OpenGWAS 367 [\(https://gwas.mrcieu.ac.uk/\)](https://gwas.mrcieu.ac.uk/). 368

Acknowledgments: The authors would like to thank deCODE, Fenland, INTERVAL and FinnGen 369 investigators for sharing their summary-level data. 370

Conflicts of Interest: The authors declare no conflict of interest. 371

372

373

Table 1. Two-sample MR estimates for associations of ABO protein with ten pregnancy outcomes 374 using instruments from deCODE, Fenland and INTERVAL 375

¹ Two SNPs were used as instruments in MR generalized inverse variance weighted method to ob- 376 tain the estimates. 377

² One SNP was used as the instrument in MR Wald ratio method to obtain the estimates. 378

It is made available under a [CC-BY 4.0 International license](http://creativecommons.org/licenses/by/4.0/) .

³ We used 5867 SNPs in the colocalization analyses. 379

Abbreviations: GDM, gestational diabeties mellitus; GH, gestational [pregnancy-induced] hyper- 380 tension; GOP, gestational [pregnancy-induced] oedema and proteinuria without hypertension; GUI, 381 infections of genitourinary tract in pregnancy, MR, Mendelian randomization, OMD, other maternal 382 disorders predominantly related to pregnancy, OMDE, other maternal diseases classifiable else- 383 where but complicating pregnancy, childbirth and the puerperium, OR, odds ratio; PL, preterm 384 labour and delivery; VH, venous complications and haemorrhoids in pregnancy. 385

386

Figure 1. Study design of two-sample Mendelian randomization exploring effects of ABO protein 387 with pregnancy outcomes Abbreviations: pQTL, protein quantitative trait loci; LD, linkage dise-
388

quilibrium; T2D, type 2 diabetes. 389

It is made available under a [CC-BY 4.0 International license](http://creativecommons.org/licenses/by/4.0/) .

significant results ($p<0.05$) among 10 outcomes tested

Figure 2. Venn diagram of Mendelian randomization estimates achieving statistical significance be- 391 fore multiple testing correction. 392

Figure 3. Two-sample Mendelian randomization estimates for associations of ABO protein with ten 394 pregnancy outcomes Abbreviations: GDM, gestational diabetes mellitus; GH, gestational [preg- 395 nancy-induced] hypertension); GUI, infections of genitourinary tract in pregnancy; GOP, gesta- 396 tional [pregnancy-induced] oedema and proteinuria without hypertension; OMD, other maternal 397 disorders predominantly related to pregnancy; OMDE, other maternal diseases classifiable else- 398 where but complicating pregnancy, childbirth and the puerperium; PL, preterm labour and deliv- 399 ery; PE, pre-eclampsia; VH, venous complications and haemorrhoids in pregnancy; SA, spontane- 400 ous abortion. 401

perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2023.10.11.23296777;](https://doi.org/10.1101/2023.10.11.23296777) this version posted October 18, 2023. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted

It is made available under a [CC-BY 4.0 International license](http://creativecommons.org/licenses/by/4.0/) .

Figure 4. Regional plots of ABO pQTL – venous complications and haemorrhoids in pregnancy with Mendelian randomization evidence of potential causality. 404

 $\frac{402}{403}$

References 405

It is made available under a [CC-BY 4.0 International license](http://creativecommons.org/licenses/by/4.0/) . perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2023.10.11.23296777;](https://doi.org/10.1101/2023.10.11.23296777) this version posted October 18, 2023. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted

perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2023.10.11.23296777;](https://doi.org/10.1101/2023.10.11.23296777) this version posted October 18, 2023. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted

